Early response predicts myeloma outcome

Abstract

In this issue of Blood, Gertz and colleagues present a retrospective study that analyzes progression-free survival and overall survival in 286 patients comparing those who did not reach a partial response or progressed during induction therapy with a regimen including thalidomide or lenalidomide to those who did achieve at least a partial response.